EYPT, US30233G2093

EyePoint Pharmaceuticals stock at 0.31 euros in evening trading

Published on 10/30/2026 at 19:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EyePoint Pharmaceuticals stock remains tied to a Phase 3 retinal-drug program. Investors are watching clinical progress as the company advances its pipeline.

Clinical pipeline drives investor focus

EyePoint is advancing DURAVYU through Phase 3 trials for wet age-related macular degeneration and diabetic macular edema.
Clinical execution remains the central near-term issue for investors.

EYPT, US30233G2093, Illustration mit AI erstellt.

EyePoint Pharmaceuticals stock traded at 0.31 euros on Lang & Schwarz at 19:32 Berlin time on Friday, October 30, 2026; the real-time quote of EyePoint Pharmaceuticals stock remains available for subsequent trading updates.

Clinical program remains central

EyePoint says it is a clinical-stage biotechnology company developing therapies for serious retinal diseases. Its lead candidate, DURAVYU, is in Phase 3 global pivotal trials for wet age-related macular degeneration and diabetic macular edema, according to the company's investor relations page.

The company listed topline data from the LUGANO Phase 3 trial among its recent corporate updates. The program's progress therefore remains a key factor for investors assessing EyePoint's development path and future funding requirements.

What investors watch next

The evening quote gives investors a current reference point for the company's US-listed shares. Further clinical updates, regulatory milestones and financial disclosures are likely to shape the next assessment of the biotechnology pipeline.